Dowling & Yahnke’s Evolent Health EVH Stock Holding History

Dowling & Yahnke’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-46,350	Closed	-$660K	–	276
2018 Q1	$660K	Sell	46,350 -60,000	-56%	-$859K	0.06%	210
2017 Q4	$1.31M	Buy	106,350 +35,000	+49%	+$493K	0.12%	172
2017 Q3	$1.27M	Hold	71,350	–	–	0.13%	162
2017 Q2	$1.81M	Sell	71,350 -45,000	-39%	-$1.08M	0.19%	137
2017 Q1	$2.6M	Buy	116,350 +25,000	+27%	+$480K	0.28%	111
2016 Q4	$1.35M	Buy	91,350 +31,350	+52%	+$618K	0.15%	155
2016 Q3	$1.48M	Buy	60,000 +20,000	+50%	+$468K	0.17%	144
2016 Q2	$768K	Buy	40,000 +20,000	+100%	+$275K	0.09%	174
2016 Q1	$211K	Buy	+20,000	New	+$207K	0.03%	247
2015 Q4	–	Sell	-30,000	Closed	-$479K	–	257
2015 Q3	$479K	Hold	30,000	–	–	0.07%	193
2015 Q2	$585K	Buy	+30,000	New	+$559K	0.07%	187

Other funds holding EVH

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Dowling & Yahnke's EVH Position: Q2 2018 in Review

Dowling & Yahnke sold out of Evolent Health (EVH) in Q2 2018, closing a stake of 46,350 shares — an estimated $660K sold.

Dowling & Yahnke first reported a position in EVH in Q2 2015 and held it in 11 quarters. The position peaked at $2.6M in Q1 2017. 178 funds tracked by Wall St. Rank hold EVH as of Q2 2018.

Dowling & Yahnke reported no remaining Evolent Health position as of Q2 2018 after selling out during the quarter.
Dowling & Yahnke sold 46,350 Evolent Health shares in Q2 2018, an estimated $660K.
Dowling & Yahnke first reported a position in Evolent Health in Q2 2015 and held it in 11 quarters.
Dowling & Yahnke's Evolent Health position peaked at $2.6M in Q1 2017.
178 funds tracked by Wall St. Rank held Evolent Health as of Q2 2018.

Based on Dowling & Yahnke's 13F filing for Q2 2018, filed 30 Jul 2018.